Article

Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccine

2020-07-20

Abstract excerpt

An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 COVID-19 vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Here we present anti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6ec874e0-ffc4-5b7d-a523-04c62852f3d8
DOI: 10.1101/2020.07.17.20140533

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccineDOI 10.1101/2020.07.17.20140533Read

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humansSemantic proximity Read

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim ReportSemantic proximity Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read

mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionSemantic proximity Read

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center studySemantic proximity Read

Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity Read

Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 yearsSemantic proximity Read

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort StudySemantic proximity Read

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adultsSemantic proximity Read

Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunitySemantic proximity Read

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in miceSemantic proximity Read

Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity Read